Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB Stock Chart & Stats
$27.48
-$0.14(-0.65%)
At close: 4:00 PM EST
$27.48
-$0.14(-0.65%)
Day’s Range― - ―
52-Week Range$17.24 - $35.43
Previous CloseN/A
Volume229.76K
Average Volume (3M)1.62M
Market Cap
$17.00B
Enterprise Value$130.98B
Total Cash (Recent Filing)$10.91B
Total Debt (Recent Filing)$35.36B
Price to Earnings (P/E)19.8
Beta0.54
Next Earnings
May 07, 2026EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding642,507,200
10 Day Avg. Volume1,968,362
30 Day Avg. Volume1,616,167
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)3.27
Price to Sales (P/S)5.13
P/FCF Ratio16.61
Enterprise Value/Market Cap7.70
Enterprise Value/Revenue9.15
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda25.43
Forecast
1Y Price Target
$37.78Price Target Upside37.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.22
Revenue Forecast (FY)$4.30B
Bulls Say, Bears Say
Bulls Say
Financial ResilienceA solid balance sheet and a track record of profitability provide financial flexibility to fund late-stage programs and absorb sector volatility.
Late-stage Clinical ReadoutsMultiple pivotal Phase III readouts for lead assets such as petosemtamab and epcoritamab could drive substantial valuation upside if they meet their primary endpoints.
Pipeline Expansion Through DealsAcquisition and licensing deals added late-stage antibody candidates, broadening the development pipeline and creating new commercial opportunities beyond legacy royalties.
Bears Say
Commercial Execution And Dilution RiskShifting from a royalty-focused model to a commercial biotech raises execution risk and could require future financing that dilutes existing shareholders.
Confirmatory Trial RiskA confirmatory trial for Epkinly failed to show the required overall survival benefit, increasing regulatory uncertainty and downside risk for that indication.
Revenue Guidance And Growth OutlookRevenue guidance came in below analyst consensus and slowing sales of an important marketed franchise suggest limited near-term growth and greater sensitivity to clinical outcomes.
Genmab News
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $17.23 and its highest was $35.43 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $17.00B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is May 07, 2026 which is in 61 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Feb 17, 2026. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.281 by -$0.231.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.16.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 642,507,200 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.05 in its last earnings report, missing expectations of $0.281. Following the earnings report the stock price went down -0.1%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GMAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genmab Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.78 (37.48% Upside)
$37.78 (37.48% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 104.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.02%
12-Months-Change
Fundamentals
Return on Equity
17.65%
Trailing 12-Months
Asset Growth
102.36%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
GMAB Company Deck
GMAB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial execution and financial performance in 2025 — including 19% total revenue growth to $3.7B, substantial proprietary product momentum (EPKINLY +67% to $468M; TIVDAK +26% to $164M), operating profit expansion to $1.26B, and strategic pipeline enhancement via the Merus acquisition (petosemtamab). Management outlined multiple near‑term clinical catalysts (up to six potential registrational readouts in 2026) and a disciplined capital allocation plan, while also acknowledging important challenges: a Phase III EPKINLY monotherapy study where OS missed statistical significance (confounded by COVID and evolving treatment landscape), higher operating expenses to fund launches and development (+13%), and increased leverage and financing costs following the acquisition. Overall, the positives — durable revenue and product growth, a deeper late‑stage pipeline with compelling early data, and clear guidance on investments and deleveraging — materially outweigh the clinical and financing risks discussed, although these risks warrant monitoring as the 2026 readouts and regulatory interactions unfold.View all GMAB earnings summariesGMAB Stock 12 Month Forecast
Average Price Target
$37.78
▲(37.48% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.81% Mutual Funds
0.53% Other Institutional Investors
97.58% Public Companies and Individual Investors